Bioray Biotech CoROCO:7561 +0.27%83 Net Margin % is 11.99% as of Dec. 2025, which is 2298% above its 10-year median of 0.50. GuruFocus rates ROCO:7561 with a GF Score™ of 83/100 and a GF Value™ of NT$29.46 (Significantly Undervalued). Among 953 Drug Manufacturers companies, Bioray Biotech Co ranks better than 77.33% on this metric.
The historical rank and industry rank for Bioray Biotech Co's Net Margin % or its related term are showing as below:
ROCO:7561'
s Net Margin % Range Over the Past 10 Years
Min: -6.03 Med: 0.5 Max: 14.48
Current: 14.48
ROCO:7561's Net Margin % is ranked better than 77.33% of 953
companies
in the Drug Manufacturers industry
Industry Median: 5.69
vs ROCO:7561: 14.48
Bioray Biotech Co (ROCO:7561) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Bioray Biotech Co Net Margin % Related Terms
Bioray Biotech Co Net Margin % Historical Data
* Premium members only.
The historical data trend for Bioray Biotech Co's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bioray Biotech Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioray Biotech Co Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bioray Biotech Co's Net Margin % distribution charts can be found below:
* The bar in red indicates where Bioray Biotech Co's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioray Biotech Co (ROCO:7561) has a Net Margin % of 11.99% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Bioray Biotech Co and its competitors. This is 2298% above median its historical median of 0.50. According to the industry distribution chart, Bioray Biotech Co ranks #216 out of 953 companies in the Drug Manufacturers industry, placing it in the top 22.7%.
Is Bioray Biotech Co's Net Margin % too high?
Bioray Biotech Co's current Net Margin % of 11.99% is 2298% above median its 10-year median of 0.50. The Drug Manufacturers industry median Net Margin % is 5.69. Bioray Biotech Co's value of 11.99% is 110.7% above this industry median. Based on the distribution chart, Bioray Biotech Co ranks #216 out of 953 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Bioray Biotech Co has a GF Score™ of 83/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bioray Biotech Co's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Bioray Biotech Co ranks #216 out of 953 companies for Net Margin %. This places Bioray Biotech Co in the top 23% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.69. Bioray Biotech Co's value of 11.99% is 110.7% above this benchmark. While the company's 10-year median is 0.50 vs. the industry median of 5.69, Bioray Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.69, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bioray Biotech Co's current Net Margin % of 11.99% is 110.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Bioray Biotech Co and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioray Biotech Co's current Net Margin % is 11.99%, which is 2298% above median its own 10-year median of 0.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioray Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Bioray Biotech Co (ROCO:7561) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$29.46, compared to a current price of NT$18.70 — trading 36.5% below its estimated fair value. The current Net Margin % is 11.99%, which is 2298% above median its 10-year median of 0.50 and 110.7% above the Drug Manufacturers industry median of 5.69. Bioray Biotech Co's overall GF Score™ is 83/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Bioray Biotech Co (ROCO:7561), the current Net Margin % is 11.99% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioray Biotech Co (ROCO:7561) Overvalued in 2026?
Based on GuruFocus' analysis, Bioray Biotech Co stock appears to be undervalued.
The current stock price of NT$18.70 is trading 36.5% below its estimated GF Value™ of NT$29.46.
GuruFocus considers Bioray Biotech Co to be Significantly Undervalued.
Key valuation signals for ROCO:7561:
Net Margin %: 11.99% (2298% above median its 10-year median of 0.50)
GF Value™: NT$29.46 vs. price of NT$18.70 (36.5% below fair value)
Industry Position: 110.7% above the Drug Manufacturers median (#216 of 953)
No single metric tells the full story. See the ROCO:7561 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioray Biotech Co Ltd is engaged in the development and manufacturing of biological agents, including functional probiotics, medicinal fungi, and immune cell preparations.
83GF Score
Get the complete analysis for ROCO:7561
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7561 has been successfully added to your 
